Resources

biosimilars in the united states
November 25, 2019
As biosimilars become more widely available in the United States, they expand therapeutic options, enhancing the likelihood that patients will be able to begin treatment with biologic medicines.
November 21, 2019
The Biosimilars Council just wrapped our annual GRx+Biosims Conference, discussing greater access to generic and biosimilar medicines for patients.
GRx+Biosims 2019
November 1, 2019
The Association for Accessible Medicines (AAM) and its Biosimilars Council are eager for the start of GRx+Biosims 2019 beginning Monday, November 4.
increasing patient access to biosimilars
October 24, 2019
Accessibility begins with educating patients, providers and payers on biosimilars, interchangeability and the safety and effectiveness of these more cost-effective treatments.
Naming Biosimilars
October 21, 2019
Biologics and biosimilars are both FDA-approved medicines that help patients treat or manage debilitating diseases. All biologic drugs are given an international non-proprietary name, but biosimilars are given a random, four-letter suffix as well.
October 2, 2019
When it comes to ensuring medicines -- including biosimilars -- are safe and effective for patients, the FDA remains the global gold standard.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER